• Contemporary ClinicContemporary Clinic
  • OTC GuideOTC Guide
  • Pharmacy Times
  • PTCEPTCE
  • Pharmacist Moms GroupPharmacist Moms Group
News
All News
FDA Updates
Press Releases
Media
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conferences
Conference Coverage
Conference Listing
Publications
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
Clinical
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Coronavirus
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
IVIG
Immunization
Immuno-oncology
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Events
Upcoming Events
Upcoming Webinars
CE
Resources
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
logo
Spotlight
Community/RetailHospitalOncologyPharmacy TechnicianStudent
Clinical Role
Community/RetailHospitalOncologyPharmacy TechnicianSpecialty PharmacyStudent
Clinical
CoronavirusBrain HealthCardiovascular HealthDermatologyDiabetesFluHeart FailureHepatitis/MASHImmunizationMigrainePneumococcalVitamins and Supplements
Supplement Spotlight
October 2023 Pharmacy Technician Edition
All News
FDA Updates
Press Releases
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conference Coverage
Conference Listing
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Coronavirus
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
IVIG
Immunization
Immuno-oncology
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Upcoming Events
Upcoming Webinars
CE
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
Advertisement

CLINICAL ROLE -

Community/Retail
| Hospital
| Oncology
| Pharmacy Technician
| Student

News

Article

May 2, 2025

Blocking IL-6 Pathway May Prevent Progression of Skin Ulcers in Calciphylaxis CKD-Related Disease

Author(s):

Gillian McGovern, Associate Editor

Key Takeaways

  • The IL6 pathway is central to skin lesion development in calciphylaxis, a CKD-related condition, and blocking it may prevent ulcers and pain.
  • Calciphylaxis is marked by painful skin ulcers and is common in end-stage kidney disease, with no current cure.
  • IL-6-tissue factor signaling is identified as a therapeutic target, with IL-6 inhibitors potentially halting disease progression.
  • Human trials are needed to confirm the efficacy of IL-6 inhibitors in preventing calciphylaxis-related skin ulcers and pain.
SHOW MORE

The condition, which is common in patients with chronic kidney disease (CKD), is characterized by skin lesions and currently has no curative treatment.

Research published in Science Translational Medicine discovered that a novel biological pathway, known as the IL6 pathway, is central to the skin lesion initiation and progression. The authors believe that by blocking this pathway, it is likely that skin ulcers resulting from a chronic kidney disease (CKD)-related condition, calciphylaxis, can be prevented and pain resolved.1,2

Chronic kidney disease written on paper with clipboard -- Image credit: Zerbor | stock.adobe.com

Image credit: Zerbor | stock.adobe.com

The overall global burden of CKD is rising, according to the investigators, with over 800 million people worldwide being affected by the disease. Vascular diseases in patients with CKD are unique and often grouped as uremic vascular diseases. A notable CKD-related condition is calciphylaxis, which is characterized by severe and painful skin ulcers, otherwise known as dermal microvessel thrombosis, that inflict painful cutaneous necrosis and currently have no known cure. It is most common in patients who have end-stage kidney disease.1,2

The findings showed that the IL-6-tissue factor (TF)-inducing ability of calciphylaxis serum was an activity marker and IL-6 was a therapeutic target for uremic calciphylaxis. Specifically, in the study, the authors demonstrate that sera from patients with calciphylaxis induced de novo synthesis of IL-6 and soluble IL-6 receptor (IL-6R), stimulated Janus kinase-2 and signal transducer, as well as activator of transcription (STAT)–3 phosphorylation in primary human dermal microvascular endothelial cells (ECs).1

In addition, the authors observed that calciphylaxis skin had an altered microenvironment that was characterized by a gain of proximal and distal IL-6 ligand-receptor interactions. Microvessels were shown to be the predominant senders and recipients of IL-6 signaling, and along with upregulated A disintegrin and metalloproteinase 17 in dermal vasculature and interstitial IL-6R, it supported trans–IL-6 signaling in calciphylaxis lesions.1

“This study reveals the presence of a pathological and harmful cycle between the fat under the skin, sweat glands, and small blood vessels that keep feeding onto itself. If this cycle isn’t stopped and remains unchecked, it will lead to the skin ulcers that won’t heal. Using the specific pathway we identified, we could break this cycle and prevent the skin ulcers from getting worse,” corresponding author Vipul Chitalia, MD, PhD, professor of medicine, explained in a news release.2

Further, calciphylaxis serum up-regulated thymidine phosphorylase (TYMP) in ECs. Because TYMP upregulated IL-6, it then activated TF, which is a primary trigger of the extrinsic coagulation cascade. IL-6–TF signaling in ECs was partially triggered by elevated IL-6 and kynurenine amounts in calciphylaxis serum, and it was inhibited by anti–IL-6 treatment.1

Additionally, TF-inducing ability of calciphylaxis serum was observed to be correlated with disease activity and response to IL-6 inhibitors in ECs. Therefore, calciphylaxis is a combination of serum-inducing TYMP–IL-6–TF signaling in ECs as well as a heterogeneous permissive local dermal microenvironment. The latter of which is characterized by microvessels that initiate IL-6 signaling and multiway crosstalk with adipocytes and eccrine glands, therefore extending the sinister thrombotic milieu.1

“Those drugs are likely to prevent progression of the skin ulcers and resolve the pain that we see in patients with calciphylaxis. Human trials are now needed to show the benefit of those drugs,” concluded coauthor Jean Francis, MD, associate professor of medicine.2

REFERENCES
1. Napoleon MA, Yang X, Zhang Y, et al. Activation and targetability of TYMP–IL-6–TF signaling in the skin microenvironment in uremic calciphylaxis. Sci. Transl. Med. 2025;17(795):eadn5772. doi:10.1126/scitranslmed.adn5772
2. Boston University School of Medicine. Researchers identify pathway responsible for calciphylaxis, a rare and serious condition. News release. April 23, 2025. Accessed April 23, 2025. https://www.eurekalert.org/news-releases/1081463
Related Videos
Menoapuse spelled with wooden blocks -- Image credit: loran4a | stock.adobe.com
Related Content
Advertisement
Ozempic, Mounjaro and Wegovy injectable pens on white background - Image credit: K KStock | stock.adobe.com
May 12th 2025

Expert Q&A: Expanding the Pharmacist's Role in Community-Based Weight Management

Emilie Collongette, PharmD, CPh, BCMTMS Kennedy Ferruggia, Assistant Editor
Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education
February 28th 2025

Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education

Luke Halpern, Assistant Editor Jill Simonian, PharmD Codi Peterson, PharmD, MS
Health care professional putting on a face mask -- Image credit: RomanR | stock.adobe.com
May 11th 2025

Study: Specialized Face Mask Accurately Detects Presence of CKD Using Chemicals in Patient’s Breath

Gillian McGovern, Associate Editor
Pharmacy Focus: World Psychedelics Day
June 14th 2024

Pharmacy Focus: World Psychedelics Day

Ashley Gallagher, Editor
Newborn baby -- Image credit: kieferpix | stock.adobe.com
May 8th 2025

INF108 Granted Orphan Drug Designation, Rare Pediatric Drug Designation for Preterm Infants With NEC

Gillian McGovern, Associate Editor
GLP-1 and Side Effects newspaper headlines with magnifying glass
May 8th 2025

Asembia AXS25: Navigating the Transformative Landscape of GLP-1 Medications

Luke Halpern, Assistant Editor
Related Content
Advertisement
Ozempic, Mounjaro and Wegovy injectable pens on white background - Image credit: K KStock | stock.adobe.com
May 12th 2025

Expert Q&A: Expanding the Pharmacist's Role in Community-Based Weight Management

Emilie Collongette, PharmD, CPh, BCMTMS Kennedy Ferruggia, Assistant Editor
Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education
February 28th 2025

Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education

Luke Halpern, Assistant Editor Jill Simonian, PharmD Codi Peterson, PharmD, MS
Health care professional putting on a face mask -- Image credit: RomanR | stock.adobe.com
May 11th 2025

Study: Specialized Face Mask Accurately Detects Presence of CKD Using Chemicals in Patient’s Breath

Gillian McGovern, Associate Editor
Pharmacy Focus: World Psychedelics Day
June 14th 2024

Pharmacy Focus: World Psychedelics Day

Ashley Gallagher, Editor
Newborn baby -- Image credit: kieferpix | stock.adobe.com
May 8th 2025

INF108 Granted Orphan Drug Designation, Rare Pediatric Drug Designation for Preterm Infants With NEC

Gillian McGovern, Associate Editor
GLP-1 and Side Effects newspaper headlines with magnifying glass
May 8th 2025

Asembia AXS25: Navigating the Transformative Landscape of GLP-1 Medications

Luke Halpern, Assistant Editor
Consent Preferences
About Us
Clinical Forums
Advertise
Contact Us
Editorial Staff
Privacy Policy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.